USEUROPEAFRICAASIA 中文雙語Fran?ais
    China
    Home / China / Society

    TCM demand grows globally

    By Liu Jie and Wang Hongyi | China Daily | Updated: 2013-02-20 07:46

    Foreign drugmakers explore opportunities in traditional Chinese medicine as the remedies become popular in Western markets, report Liu Jie in Beijing and Wang Hongyi in Shanghai

    Traditional Chinese medicine, or TCM, holds a unique place in Chinese healthcare, which is widely accepted by the 1.3 billion Chinese - old and young, urban and rural.

    Nowadays, it's also growing in popularity in Western markets, where many want to pursue a more natural lifestyle.

    International drugmakers are exploring ways, including joint ventures and co-development partnerships, to combine Western approaches to drug discovery with the material repertoire of TCM.

    "No matter the model, we believe this bodes well for the industry in general, as it may help accelerate TCM standardization and modernization, as well as TCM acceptance in overseas markets," said Bruce Liu, partner and co-head of the Pharma & Healthcare practice at Roland Berger Strategy Consultants.

    But that expansion effort faces challenges, he added.

    In November, Nestle Health Science, a fully owned subsidiary of Nestle SA, and Chi-Med, the pharmaceutical and healthcare subsidiary of Hong Kong-based Hutchison Whampoa Ltd, agreed to form a 50-50 joint venture to research, develop, manufacture and market innovative nutritional and medicinal products derived from botanical plants.

    The joint venture focuses on gastrointestinal health and may in future expand into metabolic diseases and brain health, according to Nestle.

    The new partnership gives Nestle access to the Chinese side's TCM library of more than 50,000 extracts from 1,200-plus herbal plants. Moreover, the Chinese side can offer TCM expertise and a botanical-based research and development platform, including discovery research, non-clinical and pharmaceutical science functions, and an understanding of the botanical guidelines and regulations for the joint venture.

    "This joint venture provides us with an opportunity to develop and commercialize truly innovative and scientifically validated botanical-based nutrition," said Luis Cantarell, president and CEO of Nestle Health Science.

    Other western giants have also sought out TCM opportunities. In 2009, Switzerland-based Novartis AG announced TCM-related R&D in China and plans to spend 500 million yuan ($80 million) to merge and acquire Chinese TCM enterprises in the coming years.

    UK-based pharmaceutical company GlaxoSmithKline PLC has also established a new research unit in China to carry out a molecular study in TCM.

    GSK said innovative TCM is an important part of the company's R&D in China, with a strategy of integrating the existing TCM knowledge of diseases with modern drug discovery technology and clinical trial methodology.

    At the end of 2011, Hutchison MediPharma Ltd- a subsidiary of Chi-Med - reached an agreement with international drugmaker AstraZeneca PLC for global licensing, co-development and commercialization of Volitinib, a TCM extract that halts the progress of breast and lung cancer. Under the terms of the agreement, development costs for Volitinib in China will be shared between the two sides, with Hutchison MediPharma continuing to lead the development in China. AstraZeneca will lead and pay for the development for the rest of the world.

    In addition to creating partnerships, many international pharmaceutical companies have chosen to cooperate with Chinese academic research institutes, given the local partners' rich resources of talent, basic research and academic expertise.

    France's largest drug maker, Sanofi-Aventis SA, has worked with the Hong Kong University of Science and Technology to develop modern versions of traditional Chinese medicines to treat chronic diseases such as diabetes and cancer.

    GSK has also established partnerships with academic bodies and TCM experts in China. "We are developing novel therapeutic TCM mixtures as prescription medicines through innovative extraction methods and combinations, and we use clinical data/evidence to differentiate from existing TCM products on the market," said Zang Jingwu, senior vice-president and head of GSK R&D China.

    Novartis set up a six-year research partnership with the Shanghai Institute of Materia Medica in 2009 to identify and test the pharmacological properties of some traditional medicines.

    The Shanghai institute is a unit under the Chinese Academy of Sciences and currently the largest natural-herb research base in the nation. A series of multinationals, including Johnson & Johnson Pharmaceuticals and MSD - known as Merck & Co in the United States and Canada - have established R&D cooperation agreement with the institute.

    Related:

    What is TCM?

    Previous Page 1 2 3 Next Page

    Editor's picks
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    日本欧美亚洲中文| 国产精品无码永久免费888| 久久综合精品国产二区无码| 色综合中文综合网| 911国产免费无码专区| 中文精品无码中文字幕无码专区| 中文字幕无码日韩专区| 97碰碰碰人妻视频无码| 亚洲av无码精品网站| 内射人妻少妇无码一本一道| 日本公妇在线观看中文版| 潮喷大喷水系列无码久久精品| 国产成人麻豆亚洲综合无码精品| 日韩中文字幕在线播放| 中文字幕在线观看有码| 国产仑乱无码内谢| 欧洲精品久久久av无码电影 | 国产成人无码精品久久久久免费 | 免费A级毛片无码A∨免费| 人妻少妇精品中文字幕av蜜桃| 久久青青草原亚洲av无码 | 中文日韩亚洲欧美字幕| 国产精品无码素人福利| 少妇无码AV无码专区在线观看| 中文字幕av无码专区第一页| 久久人妻无码中文字幕| 精品欧洲av无码一区二区14 | 亚洲乱亚洲乱妇无码麻豆| 亚洲欧美日韩在线不卡中文| 中文字幕夜色资源网站| 暖暖免费日本在线中文| 人妻少妇久久中文字幕一区二区| 熟妇人妻久久中文字幕| 在线播放中文字幕| 69堂人成无码免费视频果冻传媒| 中文精品久久久久人妻| 中文无码一区二区不卡αv| 一本精品中文字幕在线| 免费看成人AA片无码视频吃奶| 一本色道无码道DVD在线观看| 最新中文字幕AV无码不卡|